Budesonide, Glycopyrronium Bromide, Formoterol Fumarate Dihydrate

• Impact of Inhaled BGF 160 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient Recruiting
  2024-514097-52-00 Phase IV 1 country Centre Hospitalier Universitaire De Lille
• A study to investigate the effect of BGF MDI compared with placebo MDI on heart and lung function in participants with COPD Recruiting
  2025-521987-37-00 Phase IV 1 country AstraZeneca AB
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting
  2023-507407-59-00 Phase III 16 countries Astrazeneca AB
• A study to investigate the effect on lung function of an approved COPD treatment (BGF, with HFA propellant) compared to BGF formulated with… Ended
  2023-506565-57-00 Phase III 3 countries Astrazeneca AB
• A Study to Evaluate the Effect of BGF MDI, BFF MDI and Placebo MDI on Exercise Parameters in Participants with COPD Ended
  2022-502274-16-00 Phase III/IV 2 countries AstraZeneca AB
• "A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended
  2023-505787-11-00 Phase III 6 countries AstraZeneca AB
• A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with S… Ended
  2023-505786-88-00 Phase III 5 countries Astrazeneca AB

Showing 1–7 of 7 trials